Santos VG, Zepeda GLA, Lomelí EKV

Language: Spanish
References: 21
Page: 664-672
PDF size: 572.29 Kb.

ABSTRACT

Objective: To provide a comprehensive overview of treatment strategies for systemic lupus erythematosus, focusing on disease severity-based management, glucocorticoid utilization, and novel approaches to reduce treatment-related harm.
Methodology: An extensive analysis of current guidelines, studies, and evidence- based recommendations related to systemic lupus erythematosus treatment. We examined strategies proposed by EULAR and GLADEL for achieving remission and low disease activity based on SLE Disease Activity Index (SLEDAI) scores and medication doses.
Results: The treat to target strategy, emphasizing complete disease remission, is central in systemic lupus erythematosus management. Low disease activity has shown sustained patient adherence and protection against relapse and organ damage.
Conclusions: The optimal management of systemic lupus erythematosus entails aligning treatment with disease severity, judicious glucocorticoid use, and integration of emerging approaches to mitigate treatment-associated harm. Regular follow-up and adherence to established guidelines are crucial for achieving favorable outcomes in systemic lupus erythematosus patients.

REFERENCES

1. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Updateof the EULAR recommendations for the management ofsystemic lupus erythematosus. Ann Rheum Dis 2019; 78(6): 736-745. doi:10.1136/annrheumdis-2019-215089

2. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al. Remissionand low disease activity status (LDAS) protect lupus patientsfrom damage occurrence: data from a multiethnic,multinational Latin American Lupus Cohort (GLADEL).Ann Rheum Dis 2017; 76 (12): 2071-2074. doi:10.1136/annrheumdis-2017-211814

3. Gatto M, Zen M, Iaccarino L, Doria A. New therapeuticstrategies in systemic lupus erythematosus management.Nat Rev Rheumatol 2019; 15 (1): 30-48. doi:10.1038/s41584-018-0133-2

4. Kang JH, Shin MH, Choi SE, Xu H, Park DJ, Lee SS. Comparisonof three different definitions of low disease activityin patients with systemic lupus erythematosus and theirprognostic utilities. Rheumatol (United Kingdom) 2021; 60(2): 762-766. doi:10.1093/rheumatology/keaa407

5. Zen M, Iaccarino L, Gatto M, et al. The effect of differentdurations of remission on damage accrual: results froma prospective monocentric cohort of Caucasian patients.Ann Rheum Dis 2017; 76 (3): 562-565. doi:10.1136/ANNRHEUMDIS-2016-210154

6. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update inthe diagnosis and management of systemic lupus erythematosus.Ann Rheum Dis 2021; 80 (1): 14-25. doi:10.1136/annrheumdis-2020-218272

7. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-totargetin systemic lupus erythematosus: recommendationsfrom an international task force. Ann Rheum Dis 2014; 73(6): 958-967. doi:10.1136/ANNRHEUMDIS-2013-205139

8. Pons-Estel G, Catoggio L, Cardiel M, et al. Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus2015; 24: 536-545. doi:10.1177/0961203314567753

9. Ugarte-Gil M, Wojdyla D, Pastor-Asurza C, et al. Predictivefactors of flares in systemic lupus erythematosus patients:data from a multiethnic Latin American cohort. Lupus 2018;27: 536-544. doi:10.1177/0961203317728810

10. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al. Predictors ofremission and low disease activity state in systemic lupuserythematosus: Data from a multiethnic, multinationalLatin American Cohort. J Rheumatol 2019; 46 (10): 1299-1308. doi:10.3899/JRHEUM.180433

11. Ruiz-Irastorza G, Bertsias G. Treating systemic lupuserythematosus in the 21st century: new drugs andnew perspectives on old drugs. Rheumatol (UnitedKingdom) 2021; 59: V69-V81. doi:10.1093/rheumatology/keaa403

12. Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidencebasedrecommendations on the management of systemicglucocorticoid therapy in rheumatic diseases.Ann Rheum Dis 2007; 66 (12): 1560-1567. doi:10.1136/ard.2007.072157

13. Stahn C, Buttgereit F. Genomic and nongenomic effectsof glucocorticoids. Nat Clin Pract Rheumatol 2008; 4 (10):525-533. doi:10.1038/ncprheum0898

14. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoidsin the treatment of rheumatic diseases: Anupdate on the mechanisms of action. Arthritis Rheum 2004;50 (11): 3408-3417. doi:10.1002/art.20583

15. Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictiveuse of oral glucocorticoids in systemic lupus erythematosusand prevention of damage without worseninglong-term disease control: An observational study. ArthritisCare Res (Hoboken) 2018; 70 (4): 582-591. doi:10.1002/ACR.23322

16. Gordon C, Amissah-Arthur MB, Gayed M, et al. The BritishSociety for Rheumatology guideline for the managementof systemic lupus erythematosus in adults. Rheumatology(Oxford) 2018; 57 (1): e1-e45. doi:10.1093/rheumatology/kex286

17. Xibillé-Friedmann D, Pérez-Rodríguez M, Carrillo-VázquezS, et al. Clinical practice guidelines for the treatment ofsystemic lupus erythematosus by the Mexican Collegeof Rheumatology. Reumatol Clin 2019; 15 (1): 3-20.doi:10.1016/j.reuma.2018.03.011

18. Drosos GC, Konstantonis G, Sfikakis PP, Tektonidou MG.Underperformance of clinical risk scores in identifyingvascular ultrasound-based high cardiovascular risk insystemic lupus erythematosus. Eur J Prev Cardiol 2020:346-352. doi:10.1177/2047487320906650

19. Chowdhary VR. Broad concepts in management of systemiclupus erythematosus. Mayo Clin Proc 2017; 92 (5): 744-761.doi:10.1016/j.mayocp.2017.02.007

20. Curtis JR, Johnson SR, Anthony DD, et al. American Collegeof Rheumatology Guidance for COVID‐19 Vaccinationin Patients with Rheumatic and Musculoskeletal Diseases:Version 2. Arthritis Rheumatol 2021; 73 (8): 30-45.doi:10.1002/art.41877

21. Felten R, Kawka L, Dubois M, et al. Tolerance of COVID-19vaccination in patients with systemic lupus erythematosus:the international VACOLUP study. Lancet Rheumatol 2021;3 (9): e613-e615. doi:10.1016/s2665-9913(21)00221-6